The US National Institute of Allergy and Infectious Diseases (NIAID) says AstraZeneca may have provided incomplete data on the corona vaccine’s effectiveness.
The message of concern comes after a comprehensive US study showed that the AstraZeneca vaccine is safe and effective.
According to the study, the vaccine has 79% effectiveness against developing a symptomatic disease course and 100% effectiveness against serious illness.
AstraZeneca stated the information in a press release on Monday. The same report says that the independent research panel DSMB found “no safety problems associated with the vaccine.”
The DSMB now expresses concern that AstraZeneca may have included outdated data from the trial, which in turn may have led to an “incomplete overview of the efficacy data,” according to NIAID.
“We encourage the company to work with DSMB to review the data to ensure that the most accurate and up-to-date information is published as soon as possible,” the institute noted in a statement.
It is up to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) to approve the vaccine for use in the United States.
Source: © NTB Scanpix / #Norway Today / #NorwayTodayNews
Do you have a news tip for Norway Today? We want to hear it. Get in touch at [email protected]
Be the first to comment on "US institute fears AstraZeneca provided incomplete vaccine information"